注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

健康之路

我们需要有健康的意识,健康的知识,健康的产品及行动来维持我们身体的健康!

 
 
 

日志

 
 

喹硫平、阿立哌唑治疗精神分裂症的比较  

2016-07-14 02:15:54|  分类: 疾病与治疗 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

schizophrenia

Functional magnetic resonance imaging (fMRI) and other brain imaging technologies allow for the study of differences in brain activity in people diagnosed with schizophrenia. The image shows two levels of the brain, with areas that were more active in healthy controls than in schizophrenia patients shown in orange, during an fMRI study of working memory. Credit: Kim J, Matthews NL, Park S./PLoS One.

 

Schizophrenia is a common cause of incapacity and is ranked as the third-most-disabling illness subsequent to dementia and quadriplegia. Nearly, 75% of persons with schizophrenia have continuing problems with recurrent psychotic episodes.


Antipsychotics are effective in both the acute and chronic (maintenance) treatment of schizophrenia and other psychotic disorders. They differ in their pharmacology, kinetics, overall efficacy/effectiveness and tolerability, but perhaps more importantly, response and tolerability differs between patients. This variability of individual response means that there is no clear first line antipsychotic suitable for all patients. While there is increasing proof that most atypical antipsychotics offer benefits over typical antipsychotics, few long-term trials have openly matched SGAs. Quetiapine is a SGA with small tendency for locomotors side effects. It is prescribed for treatment of schizophrenia and other psychoses.

Aripiprazole, a partial agonist of dopamine D2 receptor, is a novel antipsychotic approved for the management of schizophrenia and bipolar I disorder. Since, in comparison with older atypical antipsychotics, like olanzapine and risperidone, aripiprazole and quetiapine are among the newest and safest SGAs, therefore in the present assessment the safety and efficacy of them had been compared with each other in a non-western patient population.

In this regard, 50 schizophrenic patients entered into two comparable groups for participation in a 12-week, double-blind study, for random assignment to quetiapine or aripiprazole. Based on the outcomes of the current study, no significant difference was evident between aripiprazole and quetiapine regarding improvement of positive and negative symptoms of schizophrenia.

For example, while both of aripiprazole and quetiapine demonstrated some efficacy in alleviation of positive symptoms, their efficacy was not so pronounced with respect to negative symptoms. General psychopathology and insight, too, revealed significant improvement with aripiprazole and quetiapine in comparison to other drugs. Also, in neither groups was there evidence of any significant increase in extrapyramidal adverse effects.

 Explore further: Atypical antipsychotics may aid symptons for some off-label uses, but not others

More information: Saeed S. Shafti et al, A Comparison Between Quetiapine and Aripiprazole for Treatment of Schizophrenia: A Double Blind Contrast, Current Psychopharmacology (2016). DOI: 10.2174/2211556005666160301231207 


Provided by: Bentham Science Publishers


  评论这张
 
阅读(37)| 评论(0)
推荐 转载

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017